Pfizer fungal infection combo flunks late-stage study; Troubled Oxygen has new chairman;

@FierceBiotech: 5 emerging biotech IT firms to watch. Feature | Follow @FierceBiotech

@ JohnCFierce: Blue Shield of California joins short list of insurers refusing to cover Avastin for breast cancer. Report | Follow @JohnCFierce

@RyanMFierce: Genome Institute of Washington U. pink slips 54 workers ahead of NIH funding cut Story | Follow @RyanMFierce

@MaureenFierce: Immune system pioneers win Nobel Prize for inspiring next-gen therapies. More | Follow @MaureenFierce

> Pfizer reported that a combo treatment failed a late-stage study on fungal infections, improving mortality rates but falling short on statistical significance.  Story

> The FDA has approved a new antibiotic--Clindamycin Injection--from Sagent Pharmaceuticals. Story

> Oxygen Biotherapeutics, which accused its recently terminated CEO Chris Stern of padding his resume, has a new chairman. Ronald Blanck was named chairman. Two directors, meanwhile, offered their resignations, shrinking the board to three. Story

> Confronted by a big funding cut, the human genome project at Washington University is laying off 54 people. Story

> Boston-based Gelesis says it has submitted new data on its new "super fiber" for promoting weight loss. Release

> California's Life Technologies is considering sites in Scotland, the U.S. and China for a major new facility. Report

Pharma News

@FiercePharma: Now with Nycomed, Takeda prescription-drug sales rank 12th globally, exec says Story | Follow @FiercePharma

> Counting the days until Zyprexa's patent runs out. Report

> FDA blames quality issues for most shortages; others blame FDA. Item

> Glaxo CEO likes sub-$2B Indian deals, dislikes M&A rules. Story

> Big CA insurer won't pay for Avastin in breast cancer. Article

> Feds probe Cephalon on Provigil, Nuvigil promos. News

Biotech IT News

> Oracle takes on translational research hurdles. Story

> Former Intel chief pushes for faster clinical research. More

> Genome Inst. at Washington U. axes 54 jobs. Report

> Ingenuity Systems aims to streamline genetic analysis. Item

> Gates-funded computer model tackles vaccine woes. Story

> Digital CRO Clinipace grabs $15M round. Item

Medical Device News

> Alere's fight for Axis-Shield heats up. Item

> Boston Sci enrolls patients in NECTAR-HF study. More

> Atlanta Catheter scores $2.98M in Series A. News

> Medtronic to create 200 jobs in PR. Article

And Finally...A new survey finds that some 13% of all adults have their own schedule for providing their children with vaccines, which may include either delaying the jab or refusing it altogether. And researchers say that the trend is likely to get much worse. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.